Study of CRTC2 pharmacology using antisense oligonuceotides

Nucleic Acid Therapeutics

Volumn 24, Issue 2, 2014, Pages 127-138

  Dullea, Robert ^a   Salatto, Christopher ^a   Sciabola, Simone ^a   Chen, Tracy ^a   Dimattia, Debra ^a   Gandhok, Harmeet ^a   Kreeger, John ^b   Weng, Yan ^c   Clark, Tracey ^c   Vage, Chandra ^c   Stanton, Robert ^a  

^a PFIZER INC   (United States)

^b Safety Science   (United States)

^c Dynamics and Metabolism   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CREB REGULATED TRANSCRIPTIONAL COACTIVATOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCAGON; LIVER ENZYME; LOCKED NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; NUCLEIC ACID; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIETARY FATS; GENE EXPRESSION REGULATION; GLUCAGON; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; LIVER; MICE; MICE, INBRED NOD; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PRIMARY CELL CULTURE; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84896945345     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0456     Document Type: Article

References (34)

1. BIJSTERBOSCH, M. K., MANOHARAN, M., RUMP, E. T., DE VRUEH, R. L. A., VAN VEGHEL, R., TIVEL, K. L., BIESSEN, E. A. L., BENNETT, C. F., COOK, P. D., and VAN BERKEL, T. J. C. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25, 3290-3296.
2. CANETTIERI, G., KOO, S., BERDEAUX, R., HEREDIA, J., HEDRICK, S., ZHANG, X., and MONTMINY, M. R. (2005). Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab. 2, 331-338.
3. CONSOLI, A., NURJHAN, N., CAPANI, F., and GERICH, J. (1989). Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38, 550-557.
4. CROOKE, R. M., GRAHAM, M. J., COOKE, M. E., and CROOKE, S. T. (1995). In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol. Exp. Ther. 275, 462-473.
5. DENTIN, R., HEDRICK, S., XIE, J., YATES, J., and MONTMINY, M. R. (2008). Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319, 1402-1405.
6. DENTIN, R., LIU, Y., KOO, S.-H., HEDRICK, S., VARGAS, T., HEREDIA, J., YATES, J., and MONTMINY, M. (2007). Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449, 366-369.
7. FRIEDEN, M., and ØRUM, H. (2008). Locked nucleic acid holds promise in the treatment of cancer. Curr. Pharm. Des. 14, 1138-1142.
8. GEARY, R. S., YU, R., SIWKOWSKI, A., and LEVIN, A. A. (2007). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology. S. T. Crooke, ed. (CRC Press, New York), pp. 305-326.
9. GONZALEZ, G. A., and MONTMINY, M. R. (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680.
10. HABENER, J. F. (1990). Cyclic AMP response element binding proteins: a cornucopia of transcription factors. Mol. Endocrinol. 4, 1087-1094.
11. HEID, C. A., STEVENS, J., LIVAK, K. J., and WILLIAMS, P. M. (1996). Real time quantitative PCR. Genome Res. 6, 986-994.
12. HOEFFLER, J. P., MEYER, T. E., YUN, Y., JAMESON, J. L., and HABENER, J. F. (1988). Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA. Science 242, 1430-1433.
13. JEPSEN, J., SORENSEN, M., and WENGEL, J. (2004). Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 14, 130-146.
14. KHETANI, S. R., and BHATIA, S. N. (2008). Microscale culture of human liver cells for drug development. Nat. Biotech. 26, 120-126.
15. KOLLER, E., VINCENT, T. M., CHAPPELL, A., DE, S., MANOHARAN, M., and BENNETT, C. F. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795-4807.
16. KOO, S., FLECHNER, L., QI, L., ZHANG, X., SCREATON, R. A., JEFFRIES, S., HEDRICK, S., XU, W., BOUSSOUAR, F., BRINDLE, P., et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111.
17. KOSHKIN, A., RAJWANSHI, V., and WENGEL, J. (1998). Novel convenient syntheses of LNA [2. 2. 1]bicyclo nucleosides. Tetrahedron Lett. 39, 4381-4384.
18. LIU, Y., DENTIN, R., CHEN, D., HEDRICK, S., RAVNSKJAER, K., SCHENK, S., MILNE, J., MEYERS, D. J., COLE, P., et al. (2008). A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269-273.
19. MEIJERINK, J., MANDIGERS, C., LOCHT, L. V. D., TÖ NNISSEN, E., GOODSAID, F., and RAEMAEKERS J. (2001). A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative realtime PCR. J. Mol. Diagn. 3, 55-61.
20. MONIA, B. P., LESNIK, E. A., GONZALEZ, C., LIMA W. F., McGee, D., GUINOSSO, C. J., Kawasaki, A. M., COOK, P. D., and FREIER S. M. (1993). Evaluation of 2-modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
21. OBIKA, S., NANBU, D., HARI, Y., ANDOH, J., MORIO, K., DOI, T., and IMANISHI, T. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2-O,4-C-methyleneribonucleosides. Tetrahedron Lett. 30, 5401-5404.
22. QI, L., SABERI, M., ZMUDA, E., WANG, Y., ALTAREJOS, J., ZHANG, X., DENTIN, R., HEDRICK, S., BANDYOPADHYAY, G., HAI, T., et al. (2009). Adipocyte CREB Promotes Insulin Resistance in Obesity. Cell Metab. 9, 277-286.
23. RAVNSKJAER, K., KESTER, H., LIU, Y., ZHANG, X., LEE, D., YATES, J. R., and MONTMINY, M. (2007). Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J. 26, 2880-2889.
24. SABERI, M., BJELICA, D., SCHENK, S., IMAMURA, T., BANDYOPADHYAY, G., LI, P., JADHAR, V., VARGEESE, C., WANG, W., and BOWMAN, K. et al. (2009). Novel liverspecific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes. Am. J. Endocrinol. Metab. 297, 1137-1146.
25. SAZANI, P., ASTRIAB-FISCHER, A., and KOLE, R. (2003). Effects of base modifications on antisense properties of 2-Omethoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev. 13, 119-128.
26. SCREATON, R. A., CONKRIGHT, M. D., KATOH, Y., BEST, J. L., CANETTIERI, G., JEFFRIES, S., GUZMAN, E., NIESSEN, S., YATES III, J. R., TAKEMORI, H. et al. (2004). The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell 119, 61-74.
27. STEIN, C. A., HANSEN, J. B., LAI, J., WU, S., VOSKRESENSKIY, A., HØG, A., WORM, J., HEDTJÄ RN, M., SOULEIMANIAN, N., MILLER P., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3.
28. WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSO T., HÖ KFELT T., BROBERGER C., PORRECA F., LAI J., REN K. et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U. S. A. 97, 5633-5638.
29. WANG, W. W., KHETANI, S. R., KRZYZEWSKI, S., DUIGNAN, D. B., and OBACH, R. S. (2010a). Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 38, 1900-1905.
30. WANG, Y., INOUE, H., RAVNSKJAER, K., VISTE, K., MILLER, N., LIU, Y., HEDRICK, S., VERA, L., and MONTMINY, M. R. (2010b). Targeted disruption of the CREB coactivator Crtc2 increases insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 107, 3087-3092.
31. WANG, Y., VERA, L., FISCHER, W. H., and MONTMINY, M. R. (2009). The CREB coactivator CRTC2 links hepatic ER stress and fasting gluconeogenesis. Nature 460, 534-537.
32. WATTS, L. M., MANCHEM, V. P., LEEDOM, T. A., RIVARD, A. L., MCKAY, R. A., BAO, D., NEROLADAKIS, T., MONIA, B. P., BODENMILLER, D. M., CAO, J. X.-C., et al. (2005). Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846-1853.
33. YU, R. Z., KIM, T.-W., HONG, A., WATANABE, T. A., GAUS, H. J., and GEARY, R. S. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35, 460-468.
34. YU, R. Z., LEMONIDIS, K. M., GRAHAM, M. J., MATSON, J. E., CROOKE, R. M., TRIBBLE, D. L., WEDEL, M. K., LEVIN, A. A., and GEARY, R. S. (2009). Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77, 910-919.